epoprostenol "campuspharma" 500 mikrogram pulver og solvens til infusionsvæske, opløsning
campuspharma ab - epoprostenolnatrium - pulver og solvens til infusionsvæske, opløsning - 500 mikrogram
fusidinsyre-hydrokortisonacetat "europharma" 10+20 mg/g creme
europharma.dk aps - fusidinsyre, hydrocortisonacetat - creme - 10+20 mg/g
colchicin "europharma" 500 mikrogram tabletter
europharma.dk aps - colchicin - tabletter - 500 mikrogram
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - clopidogrelhydrochlorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiske midler - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
rivastigmine 1 a pharma
1 a pharma gmbh - rivastigmin - alzheimer disease; dementia; parkinson disease - psychoanaleptics, - symptomatisk behandling af mild til moderat alvorlig alzheimers demens. symptomatisk behandling af mild til moderat svær demens hos patienter med idiopatisk parkinsons sygdom.
atorvastatin "pharmathen" 20 mg filmovertrukne tabletter
pharmathen s.a. - atorvastatincalcium (trihydrat) - filmovertrukne tabletter - 20 mg
atorvastatin "pharmathen" 40 mg filmovertrukne tabletter
pharmathen s.a. - atorvastatincalcium (trihydrat) - filmovertrukne tabletter - 40 mg
atorvastatin "pharmathen" 80 mg filmovertrukne tabletter
pharmathen s.a. - atorvastatincalcium (trihydrat) - filmovertrukne tabletter - 80 mg
topiramat "pharmathen" 100 mg filmovertrukne tabletter
pharmathen s.a. - topiramat - filmovertrukne tabletter - 100 mg
topiramat "pharmathen" 200 mg filmovertrukne tabletter
pharmathen s.a. - topiramat - filmovertrukne tabletter - 200 mg